Zimmer Biomet Holdings, Inc. (ZBH) Stock Price: $87.97+0.81 (+0.93%)
At close: Jun 18, 2026, 4:00 PM ET
The closing share price for Zimmer Biomet Holdings, Inc. (ZBH) stock was $87.97 for Thursday, June 18, 2026, up 0.93% on the day.
Longer view (total return, dividends reinvested): past 12 months -1.8% · 3-year avg -14.4%/yr · 5-year avg -9.8%/yr
ZBH Price Chart
ZBH is featured in
ZBH Key Metrics
See All MetricsLAST CLOSE PRICE
$87.97
52-WEEK RANGE
$79.12 - $108.29
BETA
0.47
% FROM 52W HIGH
-18.76%
MARKET CAP
$17.02B
DIVIDEND YIELD
1.09%
PE RATIO
trailing TTM
22.85
PE RATIO (FWD)
next-FY estimate
9.77
P/B RATIO
1.36
DEBT / EQUITY
0.59
REVENUE TTM
$8.41B
NET INCOME TTM
$761.30M
NET PROFIT MARGIN TTM
9.05%
TTM TOTAL RETURN
-1.84%
3Y TOTAL RETURN
-14.38%
5Y TOTAL RETURN
-9.82%
ZBH Earnings Preview
Next Earnings Date
Aug 6, 2026
47 days away
EPS Estimate
1.99
Revenue Est.
$2.14B
Last Quarter Results
EPS
$2.09
vs Estimate
$1.86
Revenue
$2.09B
vs Estimate
$2.07B
ZBH Analyst Ratings
Consensus Rating
Based on 20 analysts
Average Price Target
$98.70
+12.2% upside
Low
$83.00
Current
$87.97
High
$130.00
ZBH Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $2.05 | $2.08 | $2.12 | 6 |
| Q2 2027 | $2.20 | $2.23 | $2.27 | 6 |
| Q3 2027 | $2.10 | $2.12 | $2.16 | 6 |
| Q4 2027 | $2.60 | $2.63 | $2.68 | 6 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $8.53 | $9.01 | $9.29 | 16 |
| FY 2028 | $7.71 | $9.65 | $11.35 | 8 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $2.13B | $2.15B | $2.18B | 7 |
| Q2 2027 | $2.19B | $2.21B | $2.25B | 7 |
| Q3 2027 | $2.10B | $2.12B | $2.15B | 7 |
| Q4 2027 | $2.36B | $2.38B | $2.41B | 7 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $8.73B | $8.85B | $8.96B | 19 |
| FY 2028 | $9.18B | $9.19B | $9.20B | 18 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcareZBH Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ZBH | $17.02B | $87.97 | +0.93% | -1.84% | -9.82% | -1.68% | — |
| 2HOLX | $16.97B | $76.01 | +0.00% | +24.08% | +0.84% | +7.99% | vs ZBH |
| 3DVA | $13.34B | $207.91 | -1.27% | +53.16% | +11.32% | +10.72% | vs ZBH |
| 4MEDP | $13.14B | $460.20 | +0.68% | +52.08% | +20.99% | N/A | vs ZBH |
| 5SOLV | $13.06B | $75.43 | +1.17% | +3.86% | N/A | N/A | vs ZBH |
| 6LH | $20.98B | $255.82 | -1.44% | -1.09% | +3.80% | +9.57% | vs ZBH |
ZBH Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. (ZBH), along with its global subsidiaries, operates as a leading player in the musculoskeletal healthcare sector. The company extends its reach across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. ZBH is responsible for the design, manufacturing, and marketing of a wide array of orthopedic reconstructive solutions, including prominent knee and hip replacement systems. Their offerings also encompass Specialized Enabling Technologies (S.E.T.) products, which cover areas such as sports medicine, biologics, foot and ankle care, extremity treatments, and trauma management. Furthermore, the company provides medical devices and surgical instruments specifically for spinal conditions, alongside products for facial and cranial reconstruction. A unique part of their portfolio includes systems designed to stabilize and fixate chest bones, facilitating recovery or reconstruction following open-heart surgery, traumatic injuries, or congenital chest deformities. The company's product lines also feature a comprehensive range of dental solutions, such as reconstructive implants, prosthetics, and regenerative materials. Additionally, they are involved in robotic surgical systems, general surgical instruments, and bone cements. These advanced products and solutions are primarily utilized to address conditions in patients suffering from disorders or injuries affecting bones, joints, and their associated soft tissues. Zimmer Biomet caters to a broad clientele, including orthopedic, neuro-, and oral surgeons, dentists, hospitals, independent distributors, healthcare suppliers, and various other medical specialists. Their network further encompasses agents, healthcare purchasing organizations, and group buying alliances. Originally established in 1927, the enterprise was initially known as Zimmer Holdings, Inc., before rebranding as Zimmer Biomet Holdings, Inc. in June 2015. Its corporate headquarters are situated in Warsaw, Indiana.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ivan Tornos